The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index; none of the 13 sources its claims cite is checked for support yet.
Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
Open accessPublished version of a preprint
Abstract
The B.1.1.529/Omicron variant of SARS-CoV-2 was only recently detected in southern Africa, but its subsequent spread has been extensive, both regionally and globally 1. It is expected to become dominant in the coming weeks 2, probably due to enhanced transmissibility. A striking feature of this variant is the large number of spike mutations 3 that pose a threat to the efficacy of current COVID-19 vaccines and antibody therapies 4. This concern is amplified by the findings of our study. Here we found that B.1.1.529 is markedly resistant to neutralization by serum not only from patients who recovered from COVID-19, but also from individuals who were vaccinated with one of the four widely used COVID-19 vaccines. Even serum from individuals who were vaccinated and received a booster dose of mRNA-based vaccines exhibited substantially diminished neutralizing activity against B.1.1.529. By evaluating a panel of monoclonal antibodies against all known epitope clusters on the spike protein, we noted that the activity of 17 out of the 19 antibodies tested were either abolished or impaired, including ones that are currently authorized or approved for use in patients. Moreover, we also identified four new spike mutations (S371L, N440K, G446S and Q493R) that confer greater antibody resistance on B.1.1.529. The Omicron variant presents a serious threat to many existing COVID-19 vaccines and therapies, compelling the development of new interventions that anticipate the evolutionary trajectory of SARS-CoV-2.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
The Omicron (B.1.1.529) variant of SARS-CoV-2 shows marked resistance to neutralization by convalescent and vaccinee sera and by most tested monoclonal antibodies, including authorized therapies. The study identifies four spike mutations—S371L, N440K, G446S, and Q493R—that contribute to this antibody escape.
Key findings
- Convalescent sera from 10 individuals showed a >32-fold drop in ID50 against B.1.1.529 versus D614G, with only 2 samples above the limit of detection.
- Vaccinee sera showed substantial losses: >21-fold for BNT162b2 and >8.6-fold for mRNA-1273; all Ad26.COV2.S and ChAdOx1 nCoV-19 samples were below the limit of detection except two Ad26.COV2.S samples from previously infected individuals. Boosted mRNA vaccinees showed a mean 6.5-fold decrease against B.1.1.529.
- Among 19 monoclonal antibodies, 17 lost neutralizing activity completely or partially; class 1 and class 2 RBD antibodies decreased by more than 100-fold, while S309 and Brii-198 were spared. All four combination monoclonal antibody drugs in clinical use lost substantial activity.
- Four previously undescribed mutations—S371L, N440K, G446S, and Q493R—conferred greater antibody resistance; S371L broadly affected neutralization by monoclonal antibodies in all four RBD classes.
Methods
- Serum neutralization was tested using pseudoviruses and authentic SARS-CoV-2 isolates. Convalescent samples were collected in spring 2020 (9–120 days after symptoms); vaccinee samples included BNT162b2, mRNA-1273, Ad26.COV2.S, ChAdOx1 nCoV-19, and boosted mRNA recipients.
- A panel of 19 monoclonal antibodies (17 RBD-directed, 2 NTD-directed) was tested against B.1.1.529 and B.1.1.529+R346K pseudoviruses, and against pseudoviruses carrying each of 34 individual spike mutations.
- Neutralization curves and IC50 values were derived by nonlinear five-parameter dose-response fitting; P values were determined using two-tailed Wilcoxon matched-pairs signed-rank tests.
Limitations
- The paper states that no statistical methods were used to predetermine sample size, experiments were not randomized, and investigators were not blinded to allocation during experiments and outcome assessment.
- The paper notes that for BNT162b2 and mRNA-1273 groups, samples with high titres were specifically chosen so fold changes could be better quantified, and the difference in samples above the limit of detection may therefore be favourably biased.
- Evident from the text: the study reports in vitro neutralization only and does not measure clinical protection, in vivo efficacy, or reinfection/breakthrough outcomes directly.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
31 Own result · 11 Own method · 8 Not checked yet · 7 Own interpretation
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The most striking and perhaps unexpected finding was that S371L broadly affected neutralization by monoclonal antibodies in all four RBD classes”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Mutations conferring antibody resistance
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“a significant drop (>32-fold) in 50% infectious dose (ID 50 ) titres was observed against B.1.1.529,with only two samples showing titres above the limit of detection (LOD)”
- Also stated in: § Abstract · plain
“Here we found that B.1.1.529is markedly resistant to neutralization by serum not only from patients who recovered from COVID-19, but also from individuals who were vaccinated with one of the four widely used COVID-19 vaccines.”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Abstract
plaindirectn = 10- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“previous variants developed resistance to only NTD antibodies and class 1 and class 2 RBD antibodies”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Evolution of SARS-CoV-2 to antibodies
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For the two mRNA-based vaccines, BNT162b2 and mRNA-1273, a >21-fold and >8.6-fold decrease in ID 50 was observed, respectively.”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The activities of S309 and Brii-198 were spared.”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Antibody neutralization of B.1.1.529
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we also identified four new spike mutations (S371L, N440K, G446S and Q493R) that confer greater antibody resistance on B.1.1.529”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Strikingly, all four combination monoclonal antibody drugs in clinical use lost substantial activity against B.1.1.529”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Antibody neutralization of B.1.1.529
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“nearly all of the currently authorized or approved monoclonal antibody drugs are rendered weak or inactive by B.1.1.529”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Discussion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Within the Ad26.COV2.S and ChAdOx1 nCOV-19 groups, all of the samples were below the LOD against B.1.1.529,except for two Ad26.COV2.S samples from patients who had a previous history of SARS-CoV-2 infection”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Every sample showed lower activity in neutralizing B.1.1.529,with a mean decrease of 6.5-fold compared with the WT”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 6
- The quote only partly states this claim. 3
- Probably not a substantial claim. 14
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Again, a substantial decrease in the neutralization of B.1.1.529was observed, with mean decreases of >6.0-fold and >4.1-fold for the fully vaccinated group and the boosted group, respectively”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Q493R, which was previously shown to affect binding of CB6 and LY-CoV555 (ref.28 ) as well as polyclonal sera 29 , mediated resistance to CB6 (class 1) as well as to LY-CoV555 and 2-15 (class 2)”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Mutations conferring antibody resistance
What the sources say
- Not checked yetcites [28] Starr, T. N., Greaney, A. J., Dingens, A. S. & Bloom, J. D. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Rep. Med. 2, 100255 (2021). source
- Not checked yetcites [29] Amanat, F. et al. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. Cell 184, 3936–3948 (2021). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“its spike protein contains an alarming number of mutations (>30) (Fig. 1b and Extended Data Fig. 1), including at least 15 in the receptor-binding domain (RBD)”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“B.1.1.529,with or without R346K, has made a big mutational leap by becoming not only nearly completely resistant to class 1 and class 2 RBD antibodies, but also substantially resistant to both class 3 and class 4 RBD antibodies.”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Evolution of SARS-CoV-2 to antibodies
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Key spike mutations found in the viruses isolated in the major lineage of B.1.1.529.”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Online content
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Neutralization of D614G and B.1.1.529+R346Kpseudoviruses by RBD-directed and NTD-directed monoclonal antibodies.”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Online content
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“revealed several mutations that were not previously known to have functional importance to neutralization”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Mutations conferring antibody resistance
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
In the paper
“which is the defining mutation for the B.1.621/Muvariant 27”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Antibody neutralization of B.1.1.529
What the sources say
- Not checked yetcites [27] Uriu, K. et al. Neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine serum. N. Engl. J. Med. 385, 2397–2399 (2021). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All viruses were first titrated to normalize the viral input between assays.”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Additional information
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“No statistical methods were used to predetermine sample size.”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Data availability
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Viruses were propagated in Vero-E6-TMPRSS2 cells and the sequence was confirmed by next-generation sequencing before use.”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Additional information
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All of the participants provided written informed consent.”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Additional information
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Note that, whenever possible, we specifically chose samples with high titres against the WT strain of SARS-CoV-2 such that the loss in activity against B.1.1.529could be better quantified and the titres observed here should therefore be considered in that context.”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Additional information
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All collections were conducted under protocols reviewed and approved by the Institutional Review Board of Columbia University.”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Additional information
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment.”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Data availability
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Data represent one out of two independent experiments.”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Online content
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Cytopathic effects were then scored by plaque assay in a blinded manner.”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Additional information
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Q493R, which was previously shown to affect binding of CB6 and LY-CoV555 (ref.28 ) as well as polyclonal sera 29”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Mutations conferring antibody resistance
What the sources say
- Not checked yetcites [28] Starr, T. N., Greaney, A. J., Dingens, A. S. & Bloom, J. D. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Rep. Med. 2, 100255 (2021). source
- Not checked yetcites [29] Amanat, F. et al. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. Cell 184, 3936–3948 (2021). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“To verify the sequences of variants, next-generation sequencing libraries were prepared according to a low-volume Nextera sequencing protocol 43 and sequenced on the Illumina Miseq platform (single-end mode with 50 bp R1).”
- Also stated in: § Additional information · plain
“The resulting reads alignments were then visualized in the Integrative Genomics Viewer 46 and manually inspected to verify the fidelity of variants.”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Additional information
What the sources say
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Also stated in: § Additional information · plain
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Cells were purchased from authenticated vendors and morphology was confirmed visually before use.”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Additional information
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All cell lines tested mycoplasma negative.”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Additional information
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The authors state this as an assumption.
Patients with COVID-19 in spring 2020 were infected with WT SARS-CoV-2.
“who were presumably infected with the wild-type (WT) SARS-CoV-2”
The paper relies on this without support.
In vitro neutralization activity of monoclonal antibodies predicts their clinical efficacy in patients.
“probably abolishing or impairing their efficacy in patients”
The paper relies on this without support.
Neutralizing antibody titres are a correlate of protection against SARS-CoV-2 infection.
“Collectively, these results suggest that individuals who were previously infected or fully vaccinated remain at risk for B.1.1.529infection.”
The authors state this as an assumption.
Convalescent plasma samples were infected by the WT strain of SARS-CoV-2.
“These samples were collected at the beginning of the pandemic in early 2020 at Columbia University Irving Medical Center and are therefore assumed to be infection by the WT strain of SARS-CoV-2 (ref. 4 ).”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similar findings suggest that vaccination with three doses of the mRNA vaccine BNT162b2 may protect against Omicron-mediated COVID-19.407,408”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [407]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > Abstract
“The short doubling time (2-3 days) of Omicron cases suggests that it could soon become dominant 2 .”
§ Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 > References
“Omicron strain spreads with the doubling time of 3.2-3.6 days in South Africa province of Gauteng that achieved herd immunity to Delta variant.”
Citations
Cites
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Cutadapt removes adapter sequences from high-throughput sequencing reads
Martin, M. (2011) · EMBnet.journal · doi:10.14806/ej.17.1.200 · Cited by 33,889
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
Inference of Macromolecular Assemblies from Crystalline State
Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 10,007
Nextstrain: real-time tracking of pathogen evolutionPreprint
Hadfield, J., Megill, C., Bell, S. M., et al. (2017) · bioRxiv · doi:10.1101/224048 · Cited by 3,172
Nextstrain: real-time tracking of pathogen evolution
Hadfield, J., Megill, C., Bell, S. M., Huddleston, J., Potter, B., Callender, C., Sagulenko, P., Bedford, T., & Neher, R. A. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty407 · Cited by 3,154
GISAID: Global initiative on sharing all influenza data – from vision to reality
Shu, Y., & McCauley, J. (2017) · Eurosurveillance · doi:10.2807/1560-7917.es.2017.22.13.30494 · Cited by 3,039
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2021) · Science · doi:10.1126/science.abg3055 · Cited by 2,581
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2020) · doi:10.1101/2020.12.24.20248822 · Cited by 2,557
Detection of a SARS-CoV-2 variant of concern in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510
Research works printed but not linked: 1
- Grabowski, F., Kochańczyk, M. & Lipniacki, T. Omicron strain spreads with the doubling time of 3.2—3.6 days in South Africa province of Gauteng that achieved herd immunity to Delta variant. Preprint at https://doi.org/10.1101/2021.12.08.21267494 (2021). · DOI
Cited by
Sorted by citations
Items 301–400 of 1,001
Strohl, W. R., Ku, Z., An, Z., Carroll, S. F., Keyt, B. A., & Strohl, L. M. (2022) · BioDrugs · doi:10.1007/s40259-022-00529-7 · Cited by 35
Omicron BA.1 and BA.2 variants increase the interactions of SARS-CoV-2 spike glycoprotein with ACE2
Gölcük, M., Yıldız, A., & Gür, M. (2022) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2022.108286 · Cited by 34
Wang, L., Wang, S., Wu, L., Li, W., Bray, W. A., Clark, A. E., Gonzalez, G. M., Wang, Y., Carlin, A. F., & Rana, T. M. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2210361120 · Cited by 35
Braet, S. M., Buckley, T. S., Venkatakrishnan, V., Dam, K.-M. A., Björkman, P. J., & Anand, G. S. (2023) · eLife · doi:10.7554/elife.82584 · Cited by 36
Shen, X. (2022) · Nature Medicine · doi:10.1038/s41591-022-01727-0 · Cited by 34
Omicron variant evolution on vaccines and monoclonal antibodies
Sabbatucci, M., Vitiello, A., Clemente, S., Zovi, A., Boccellino, M., Ferrara, F., Cimmino, C., Langella, R., Ponzo, A., Stefanelli, P., et al. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01253-6 · Cited by 33
Müller, T. R., Sekine, T., Trubach, D., Niessl, J., Chen, P., Bergman, P., Blennow, O., Hansson, L., Mielke, S., Nowak, P., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adg9452 · Cited by 34
Menéndez, J. C. (2022) · Molecules · doi:10.3390/molecules27030658 · Cited by 33
Mader, A.-L., Tydykov, L., Glück, V., Bertok, M., Weidlich, T., Gottwald, C., Stefl, A., Vogel, M., Plentz, A., Köstler, J., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104076 · Cited by 33
Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody
Torres, J. L., Ozorowski, G., Andreano, E., Liu, H., Copps, J., Piccini, G., Donnici, L., Conti, M., Planchais, C., Planas, D., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2120976119 · Cited by 33
Atanackovic, D., Luetkens, T., Omili, D. O., Iraguha, T., Lutfi, F. U., Hardy, N. M., Fan, X., Avila, S. V., Saharia, K., Husson, J. S., et al. (2022) · Blood · doi:10.1182/blood.2022016175 · Cited by 35
Aiello, A., Coppola, A., Vanini, V., Petrone, L., Cuzzi, G., Salmi, A., Altera, A. M. G., Tortorella, C., Gualano, G., Gasperini, C., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.07.049 · Cited by 32
Li, Q., Liu, X., Li, L., Hu, X., Cui, G., Sun, R., Zhang, D., Li, J., Li, Y., Zhang, Y., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.944909 · Cited by 32
Evering, T. H., Chew, K. W., Giganti, M. J., Moser, C., Pinilla, M., Wohl, D. A., Currier, J. S., Eron, J. J., Javan, A. C., Ignacio, R. B., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m22-3428 · Cited by 32
A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants
Weinstein, J. B., Bates, T. A., Leier, H. C., McBride, S. K., Barklis, E., & Tafesse, F. (2022) · iScience · doi:10.1016/j.isci.2022.103960 · Cited by 31
Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529
Wang, Q., Anang, S., Iketani, S., Guo, Y., Liu, L., Katsamba, P. S., Shapiro, L. S., Ho, D. D., & Sodroski, J. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110924 · Cited by 34
Self-citationA broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge
Zhou, B., Zhou, R., Tang, B., Chan, J. F., Luo, M., Peng, Q., Yuan, S., Liu, H., Mok, B. W.-Y., Chen, B., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31259-7 · Cited by 32
Self-citationStrizki, J., Gaspar, J. M., Howe, J. A., Hutchins, B., Mohri, H., Nair, M. S., Kinek, K. C., McKenna, P. M., Goh, S. L., & Murgolo, N. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00953-23 · Cited by 33
Self-citationThe Importance of Measuring SARS-CoV-2-Specific T-Cell Responses in an Ongoing Pandemic
Petrone, L., Sette, A., de Vries, R. D., & Goletti, D. (2023) · Pathogens · doi:10.3390/pathogens12070862 · Cited by 31
Potential immune evasion of the severe acute respiratory syndrome coronavirus 2 Omicron variants
Chen, L., He, Y., Liu, H., Shang, Y., & Guo, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1339660 · Cited by 32
An update on the anti-spike monoclonal antibody pipeline for SARS-CoV-2
Focosi, D., Franchini, M., Casadevall, A., & Maggi, F. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.04.012 · Cited by 31
Cedro‐Tanda, A., Gómez-Romero, L., de Anda‐Jáuregui, G., Garnica-López, D., Alfaro‐Mora, Y., Sánchez-Xochipa, S., García-García, E. F., Mendoza-Vargas, A., Frías-Jiménez, E., Moreno, B., et al. (2022) · Viruses · doi:10.3390/v14030545 · Cited by 31
Lin, Y., Yue, S., Yang, Y., Yang, S., Pan, Z., Yang, X., Gao, L., Zhou, J., Li, Z., Li, H., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac448 · Cited by 31
Liu, H., Kaku, C. I., Song, G., Yuan, M., Andrabi, R., Burton, D. R., Walker, L. M., & Wilson, I. A. (2022) · Communications Biology · doi:10.1038/s42003-022-03700-6 · Cited by 32
Inhalable neutralizing antibodies – promising approach to combating respiratory viral infections
Chow, M. Y. T., Pan, H. W., Seow, H. C., & Lam, J. K. W. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.11.006 · Cited by 32
Therapeutics to Tackle Omicron Outbreak
Chavda, V. P., Ghali, E. N. H. K., Yallapu, M. M., & Apostolopoulos, V. (2022) · Immunotherapy · doi:10.2217/imt-2022-0064 · Cited by 31
Zhao, X., Qiu, T., Huang, X., Mao, Q., Wang, Y., Qiao, R., Li, J., Mao, T., Wang, Y., Cun, Y., et al. (2024) · Cell Discovery · doi:10.1038/s41421-024-00648-1 · Cited by 30
Self-citationLechmere, T., Snell, L. B., Graham, C., Seow, J., Shalim, Z. A., Charalampous, T., Alcolea-Medina, A., Batra, R., Nebbia, G., Edgeworth, J. D., et al. (2022) · mBio · doi:10.1128/mbio.03798-21 · Cited by 30
Wang, S., Sun, H., Zhang, Y., Yuan, L., Wang, Y., Zhang, T., Wang, S., Zhang, J., Yu, H. J., Xiong, H., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110862 · Cited by 30
Self-citationFang, Y., Sun, P., Xie, X., Du, M., Du, F., Ye, J., Kalveram, B., Plante, J. A., Plante, K. S., Li, B., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abp9962 · Cited by 30
Liu, B. C., Gidding, H. F., Stepien, S., Cretikos, M. A., & Macartney, K. K. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.09.029 · Cited by 30
Wang, Y.-D., Zhang, X., Ma, Y., Wang, Y., Zhan, W., Zheng, Q., Zhang, M., Ji, P., Liu, M., Liu, Q., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00463-6 · Cited by 30
Scarpa, F., Sanna, D., Benvenuto, D., Borsetti, A., Azzena, I., Casu, M., Fiori, P. L., Giovanetti, M., Maruotti, A., Ceccarelli, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315264 · Cited by 30
Rzymski, P., Pokorska‐Śpiewak, M., Jackowska, T., Kuchar, E. P., Nitsch-Osuch, A. S., Pawłowska, M., Babicki, M., Jaroszewicz, J., Szenborn, L., Wysocki, J., et al. (2023) · Vaccines · doi:10.3390/vaccines11091502 · Cited by 31
Immune Evasion of SARS-CoV-2 Omicron Subvariants
Ke, H., Chang, M., & Marasco, W. A. (2022) · Vaccines · doi:10.3390/vaccines10091545 · Cited by 29
Song, G., Yuan, M., Liu, H., Capozzola, T., Lin, R. N., Torres, J. L., He, W., Musharrafieh, R., Dueker, K., Zhou, P.-P., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115948 · Cited by 30
Lu, L., Chen, L., Zhang, R., Tsang, O. T., Chan, J. M., Tam, A. R., Leung, W.-S., Chik, T. S., Lau, D. P.-L., Choi, C. Y.-C., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103986 · Cited by 30
Self-citationFiles, D. C., Tacke, F., O’Sullivan, A., Dorr, P. K., Ferguson, W., & Powderly, W. G. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010547 · Cited by 29
Ohashi, H., Hishiki, T., Akazawa, D., Kim, K. S., Woo, J., Shionoya, K., Tsuchimoto, K., Iwanami, S., Moriyama, S., Kinoshita, H., et al. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105372 · Cited by 29
Roberts, D. S., Mann, M. W., Li, B. H., Kim, D., Braiser, A. R., Jin, S., & Ge, Y. (2022) · Chemical Science · doi:10.1039/d2sc02132c · Cited by 29
Jeong, H. W., Kim, S., Jung, M. K., Noh, J. Y., Yoo, J., Kim, E.-H., Kim, Y., Yu, K.-M., Jang, S., Gil, J., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100764 · Cited by 29
Verkhivker, G. M., Alshahrani, M., & Gupta, G. (2023) · Viruses · doi:10.3390/v15051143 · Cited by 29
SARS-CoV-2 and the host-immune response
Maison, D. P., Deng, Y., & Gerschenson, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1195871 · Cited by 29
Structural Immunology of SARS ‐ CoV ‐2
Yuan, M., & Wilson, I. A. (2024) · Immunological Reviews · doi:10.1111/imr.13431 · Cited by 29
Wickenhagen, A., Flagg, M., Port, J. R., Yinda, C. K., Goldin, K., Gallogly, S., Schulz, J. E., Lutterman, T. R., Williamson, B. N., Kaiser, F. K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-55938-3 · Cited by 28
SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2
Wang, R., Zhang, Q., Zhang, R., Aw, Z. Q., Chen, P., Wong, Y. H., Hong, J., Ju, B., Shi, X., Ding, Q., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.854952 · Cited by 29
Sub‐lineages of the SARS‐CoV‐2 Omicron variants: Characteristics and prevention
Xu, A., Hong, B., Lou, F., Wang, S., Li, W., Shafqat, A., An, X., Zhao, Y., Song, L., Tong, Y., et al. (2022) · MedComm · doi:10.1002/mco2.172 · Cited by 30
Suzuki, S., Geri, J. B., Knutson, S. D., Bell‐Temin, H., Tamura, T., Fernández, D. F., Lovett, G. H., Till, N. A., Heller, B. L., Guo, J., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c06806 · Cited by 28
Enhanced recombination among Omicron subvariants of SARS‐CoV‐2 contributes to viral immune escape
Shiraz, R., & Tripathi, S. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28519 · Cited by 28
Wu, J., Chen, Z., Gao, Y., Wang, Z., Wang, J., Chiang, B., Zhou, Y., Han, Y., Zhan, W., Xie, M., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112503 · Cited by 28
An IgM-like inhalable ACE2 fusion protein broadly neutralizes SARS-CoV-2 variants
Liu, J., Mao, F., Chen, J., Lu, S., Qi, Y., Sun, Y., Fang, L., Yeung, M. L., Liu, C., Yu, G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40933-3 · Cited by 29
Self-citationIdentification of a Novel SARS-CoV-2 Delta-Omicron Recombinant Virus in the United StatesPreprint
Lacek, K. A., Rambo‐Martin, B. L., Batra, D. G., Zheng, X.-Y., Sakaguchi, H., Peacock, T. P., Keller, M. W., Wilson, M. M., Sheth, M., Davis, M. L., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.19.484981 · Cited by 28
Post-vaccination and post-infection humoral immune response to the SARS-CoV-2 infection
Andreev, I. V., Nechay, K. O., Andreev, A. I., Zubaryova, A. P., Esaulova, D. R., Alenova, A. M., Ia, N., Chernyavskaya, O. P., Lomonosov, K. S., Евгеньевич, Ш. А., et al. (2022) · Immunologiya · doi:10.33029/0206-4952-2022-43-1-18-32 · Cited by 28
Greaney, A. J., Eguia, R. T., Starr, T. N., Khan, K., Franko, N., Logue, J. K., Lord, S. M., Speake, C., Chu, H. Y., Sigal, A., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010592 · Cited by 29
Self-citationSu, W., Choy, K. T., Gu, H., Sia, S. F., Cheng, K. M., Nizami, S. I. N., Krishnan, P., Ng, Y. M., Chang, L. D. J., Liu, Y., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac276 · Cited by 27
Yuan, M., Chen, X., Zhu, Y., Dong, X., Liu, Y., Qian, Z., Ye, L., & Liu, P. (2022) · Journal of Virology · doi:10.1128/jvi.00775-22 · Cited by 27
Santra, D., & Maiti, S. (2022) · Structural Chemistry · doi:10.1007/s11224-022-02022-x · Cited by 27
Zhang, J., Han, Z. B., Liang, Y., Zhang, X. F., Jin, Y. Q., Du, L. F., Shao, S., Wang, H., Hou, J. W., Xu, K., et al. (2022) · eLife · doi:10.7554/elife.78633 · Cited by 29
Self-citationMolecular analysis of a public cross-neutralizing antibody response to SARS-CoV-2
Yuan, M., Wang, Y., Lv, H., Tan, T. J. C., Wilson, I. A., & Wu, N. C. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111650 · Cited by 27
Sokhansanj, B. A., Zhao, Z., & ROSEN, G. L. (2022) · Biology · doi:10.3390/biology11121786 · Cited by 27
Wonder of wonders, miracle of miracles: the unprecedented speed of COVID-19 science
Saag, M. S. (2022) · Physiological Reviews · doi:10.1152/physrev.00010.2022 · Cited by 28
Chen, K., Xu, Y., Li, J., Gu, S., Wang, Z., Li, J., & Zhang, Y. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102687 · Cited by 29
Rajpal, V. R., Sharma, S., Kumar, A., Chand, S., Joshi, L., Chandra, A., Babbar, S., Goel, S., Raina, S. N., & Shiran, B. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27749 · Cited by 26
Li, Q., Zhang, M., Liang, Z., Zhang, L., Wu, X., Yang, C., An, Y., Tong, J., Liu, S., Li, T., et al. (2022) · MedComm · doi:10.1002/mco2.130 · Cited by 26
Molecular aspects of Omicron, vaccine development, and recombinant strain XE: A review
Akash, K., Sharma, A. K., Kumar, D., Singh, S. K., Gupta, G., Chellappan, D. K., Dua, K., & Nagraik, R. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27936 · Cited by 26
Structural Basis of Main Proteases of Coronavirus Bound to Drug Candidate PF-07304814
Li, J., Lin, C., Zhou, X., Zhong, F., Zeng, P., McCormick, P. J., Jiang, H., & Zhang, J. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167706 · Cited by 26
Yan, B., Yuan, S., Cao, J., Fung, K., Lai, P.-M., Yin, F., Sze, K. H., Qin, Z., Xie, Y., Ye, Z., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.73057 · Cited by 26
Self-citationVillamarín, M., Márquez‐Algaba, E., Esperalba, J., Perelló, M., Arcos, I. L., Campany, D., Moreso, F., & Len, Ó. (2022) · Transplantation · doi:10.1097/tp.0000000000004306 · Cited by 26
Ali, A. M., Tofiq, A. M., Rostam, H. M., Ali, K. M., & Tawfeeq, H. M. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28098 · Cited by 26
Lubin, J. H., Markosian, C., Balamurugan, D., Ma, M. T., Chen, C.-H., Liu, D., Pasqualini, R., Arap, W., Burley, S. K., & Khare, S. D. (2023) · JCI Insight · doi:10.1172/jci.insight.168296 · Cited by 26
Wang, X., Chen, X., Tan, J., Yue, S., Zhou, R., Xu, Y., Lin, Y., Yang, Y., Zhou, Y. W., Deng, K., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.03.035 · Cited by 25
Saharia, K., Husson, J. S., Niederhaus, S. V., Iraguha, T., Avila, S. V., Yoo, Y. J., Hardy, N. M., Fan, X., Omili, D. O., Crane, A., et al. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1391 · Cited by 26
Suntronwong, N., Kanokudom, S., Auphimai, C., Assawakosri, S., Thongmee, T., Vichaiwattana, P., Duangchinda, T., Chantima, W., Pakchotanon, P., Chansaenroj, J., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28044 · Cited by 25
Early Detection of SARS-CoV-2 Omicron BA.4 and BA.5 in German Wastewater
Wilhelm, A., Agrawal, S., Schoth, J., Meinert‐Berning, C., Bastian, D., Orschler, L., Ciesek, S., Teichgräber, B., Wintgens, T., Lackner, S., et al. (2022) · Viruses · doi:10.3390/v14091876 · Cited by 25
Genomic profile of SARS-CoV-2 Omicron variant and its correlation with disease severity in Rajasthan
Sharma, R., Gautam, S., Sharma, P., Singh, R., Sharma, H., Parsoya, D., Deeba, F., Bhomia, N., Pal, N., Potdar, V. A., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.888408 · Cited by 25
METTL3 modulates chromatin and transcription dynamics during cell fate transition
Liu, X., Mao, Y., Wang, S., Zhou, J. L., & Qian, S. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04590-x · Cited by 25
Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics
Pavan, M., & Moro, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054401 · Cited by 25
SARS-CoV-2 before and after Omicron: two different viruses and two different diseases?
Gili, R., & Burioni, R. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04095-6 · Cited by 25
An immunostimulatory glycolipid that blocks SARS-CoV-2, RSV, and influenza infections in vivo
Tsuji, M., Nair, M. S., Masuda, K., Castagna, C., Chong, Z., Darling, T. L., Seehra, K., Hwang, Y., Ribeiro, Á. L., Ferreira, G. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39738-1 · Cited by 25
Self-citationCohen, D., Izak, M., Stoyanov, E., Mandelboim, M., Perlman, S., Amir, Y., Goren, S., Bialik, A., Kliker, L., Atari, N., et al. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.04.395 · Cited by 25
Genetically modified crops and sustainable development: navigating challenges and opportunities
Sandhu, R., Chaudhary, N., Shams, R., & Dash, K. K. (2024) · Food Science and Biotechnology · doi:10.1007/s10068-024-01669-y · Cited by 24
Cross-reactive sarbecovirus antibodies induced by mosaic RBD nanoparticles
Fan, C., Keeffe, J. R., Malecek, K. E., Cohen, A. A., West, A. P., Baharani, V. A., Rorick, A. V., Gao, H., Gnanapragasam, P. N. P., Rho, S., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2501637122 · Cited by 23
Pavan, M., Bassani, D., Sturlese, M., & Moro, S. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2081847 · Cited by 24
Covid-EnsembleNet: An Ensemble Based Approach for Detecting Covid-19 by utilising Chest X-ray Images
Al-Monsur, A., Kabir, M. R., Ar-Rafi, A. M., Nishat, M. M., & Faisal, F. (2022) · IEEE World AI IoT Congress (AIIoT) · doi:10.1109/aiiot54504.2022.9817237 · Cited by 24
Bruel, T., Pinaud, L., Tondeur, L., Planas, D., Staropoli, I., Porrot, F., Guivel‐Benhassine, F., Attia, M., Pelleau, S., Woudenberg, T., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101576 · Cited by 25
Zarębska‐Michaluk, D., Hu, C., Brzdęk, M., Flisiak, R., & Rzymski, P. (2022) · Vaccines · doi:10.3390/vaccines10081223 · Cited by 24
Benning, L., Morath, C. P., Kühn, T., Bartenschlager, M., Kim, H., Beimler, J., Buylaert, M., Nußhag, C., Kälble, F., Reineke, M., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.958293 · Cited by 25
Lee, M., Kang, B., Lee, J., Lee, J., Jung, S. T., Son, C. Y., & Oh, S. S. (2022) · Science Advances · doi:10.1126/sciadv.abq6207 · Cited by 24
A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19
Haddad, F., Dokmak, G., & Karaman, R. (2022) · Life · doi:10.3390/life12111758 · Cited by 25
Comparative analysis of SARS‐CoV‐2 Omicron BA.2.12.1 and BA.5.2 variants
Ong, C. P., Ye, Z., Tang, K., Liang, R., Xie, Y., Zhang, H., Qin, Z., Sun, H., Wang, T.-Y., Cheng, Y., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28326 · Cited by 24
Self-citationResearch progress in spike mutations of SARS‐CoV‐2 variants and vaccine development
He, X., He, C., Hong, W., Yang, H. J., & Wei, X. (2023) · Medicinal Research Reviews · doi:10.1002/med.21941 · Cited by 25
COV2Var, a function annotation database of SARS-CoV-2 genetic variation
Feng, Y., Yi, J., Yang, L., Wang, Y., Wen, J., Zhao, W., Kim, P., & Zhou, X. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad958 · Cited by 26
Li, D., Zhou, H., Ren, Z., Xu, C., & Lee, C. (2024) · Nano-Micro Letters · doi:10.1007/s40820-024-01520-3 · Cited by 26
PPB-Affinity: Protein-Protein Binding Affinity dataset for AI-based protein drug discovery
Liu, H., Chen, P., Zhai, X., Huo, K.-G., Zhou, S., Han, L., & Fan, G. (2024) · Scientific Data · doi:10.1038/s41597-024-03997-4 · Cited by 30
Structural review of SARS-CoV-2 antiviral targets
Cui, W., Duan, Y., Gao, Y., Wang, W., & Yang, H. (2024) · Structure · doi:10.1016/j.str.2024.08.005 · Cited by 24
Analysis of the Protective Efficacy of Approved COVID-19 Vaccines Against Various Mutants
Li, C., Guo, Y., Fang, Z., Zhang, H., Zhang, Y., & Chen, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.804945 · Cited by 23
Self-citationde Araújo, J. C., Mota, V. T., TEODORO, A. L. S., Leal, C. D., Leroy-Freitas, D., Madeira, C. L., Machado, E. C., Dias, M. F., Souza, C. C., Coelho, G., et al. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.155959 · Cited by 23
Emmelot, M. E., Vos, M. W., Boer, M. C., Rots, N. Y., de Wit, J., van Els, C. A. C. M., & Kaaijk, P. (2022) · Viruses · doi:10.3390/v14071570 · Cited by 23
Vaccines against SARS-CoV-2 variants and future pandemics
Park, T., Hwang, H., Moon, S., Kang, S. G., Song, S., Kim, Y. H., Kim, H., Ko, E., Yoon, S., Kang, S., et al. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2110075 · Cited by 23
Madhi, S. A., Kwatra, G., Richardson, S. I., Koen, A. L., Baillie, V. L., Cutland, C., Fairlie, L., Padayachee, S. D., Dheda, K. U. J., Barnabas, S. L., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00596-5 · Cited by 25
Metadata
- Authors
- Liu, L., Iketani, S., Guo, Y., Chan, J. F.-W., Wang, M., Liu, L., Luo, Y., Chu, H., Huang, Y., Nair, M. S., Yu, J., Chik, K. K.-H., Yuen, T. T.-T., Yoon, C., To, K. K.-W., Chen, H., Yin, M. T., Sobieszczyk, M. E., Huang, Y., Wang, H. H., Sheng, Z., Yuen, K.-Y., & Ho, D. D.
- Affiliations
- Aaron Diamond AIDS Research Center (US)
- University of Hong Kong (HK)
- Columbia University (US)
- Corresponding author
- Ho, David D.
- ORCID
- Venue
- Nature
- Published
- 2021-12-23
- Volume
- 602
- Issue
- 7898
- Pages
- 676-681
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W4220904663
- Cited by
- 1,290
- References
- 47
- Citations by year
- 2026: 60 · 2025: 107 · 2024: 179 · 2023: 341 · 2022: 598 · 2021: 5
- FWCI
- 89.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Science Foundation (2032259)
- Bill and Melinda Gates Foundation
- JPB Foundation
- Regeneron Pharmaceuticals
- Irving Medical Center, Columbia University
- National Institute of Allergy and Infectious Diseases
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Keywords
- Omicron variant, SARS-CoV-2, antibody escape, neutralizing antibodies, spike protein mutations, vaccine escape, COVID-19 vaccines, monoclonal antibodies, booster vaccination, serum neutralization
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, Antibodies, Monoclonal, Antibodies, Viral, Cell Line, Convalescence, Humans, Immune Sera, Models, Molecular, Mutation, Neutralization Tests, Evolution, Molecular, Inhibitory Concentration 50, Immune Evasion, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
